Medico Remedies Limited (MEDICO) fundamentals
Medico Remedies Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as MEDICO (ISIN INE630Y01024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Medico Remedies Limited does
Medico Remedies Limited is an India-based company, principally engaged in the pharmaceutical business. The Company is involved in the development, manufacture and sale of pharmaceutical and nutraceutical products. It focuses on anti-infective, Beta-Lactams, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, hematinic and other supplements. The Company also manufactures and markets capabilities in other drugs such as non-steroidal anti-inflammatory drugs (NSAIDS), antihistaminic, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream and gel for various therapeutic segments. Its products include Doxycycline Capsules, Zenof-400 (Ofloxacin Tablets 400mg), Azithromycin Tablets, Aciclovir Tablets, Cipta Tablets, Cotrimoxazole Tablets, Tos Syrup, Pediatric Co-Trimozole Oral, Med Reactin (Cyproheptadine), and Medivit Syrup, among others. Its syrups include Medivit Syrup and Ferrovit Syrup.
Valuation and market data
| Last close | ₹37.05 |
|---|---|
| Market capitalisation | ₹306 crore |
| Enterprise value | ₹306 crore |
| P/E (TTM) | 0.00 |
| Price to book | 4.91 |
| Price to sales (TTM) | 1.26 |
| Book value per share | ₹7.55 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu May 26 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹212 crore | ₹18 crore | ₹13 crore | 0.00 |
| Mar 2025 | ₹154 crore | ₹14 crore | ₹10 crore | 1.22 |
| Mar 2024 | ₹147 crore | ₹11 crore | ₹8 crore | 1.00 |
| Mar 2023 | ₹144 crore | ₹10 crore | ₹7 crore | 0.87 |
| Mar 2022 | ₹123 crore | ₹6 crore | ₹5 crore | 0.58 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 61.4% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 38.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.